Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients

NCT02434484 is registered in ClinicalTrials.gov with Eisai Korea Inc. as lead sponsor.

NCT NCT02434484
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT02434484 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Post-Marketing Surveillance of Symbenda Injection (Bendamustine Hydrochloride) in Korean Patients
Lead sponsor
Eisai Korea Inc.
Phase
Observational
Overall status
Completed
Start date
July 4, 2018
Completion date
March 20, 2020
Enrollment
84 (actual)
Sites
9

Conditions

As the registry lists them; a condition with its own page is linked.

lymphocytic leukemia, lymphoma, non-hodgkin, multiple myeloma